

via email

Ms G Fletcher-Cooke

Ref: FC315

From: Dr A Rejman HCD-SCS

Date: 31 May 1995

Copy: Dr Bourdillon

Mr Podger\*
Mr Scofield o/r\*
Mr Waterhouse\*
Mr M Brown\*
Dr Ludgate\*
Dr Kennedy\*

Mr J G Brown - amended entry

Mr Kingham\* Mr Ferrero\*

\* Minute only

#### SCS-B - SLAs DR A REJMAN

 I enclose draft notes on the subject of the various SLAs covering my work, together with the approximate amount of staff time covered.

- I have incorporated amendments where I have received them from copy recipients who
  received earlier drafts last week.
- 3. The hours quoted for each SLA are estimated on the basis of work in 1994/95, based on a 37½ hour notional week. In addition to these SLAs, 3.7 hours a week is spent on clinical work at St Thomas' Hospital, and 1.6 hours in SCS-B5, my parent team.
- 4. At an internal communications meeting last Friday, I was informed that apparently there are guidelines available in DM for preparing SLAs within the Department. I was unaware of this, and others at that meeting, together with some of the copy recipients were also not aware of the existence of these guidelines.

Dr A Rejman Room 420 Ext GRO-C

#### DRAFT SLA BETWEEN DR A REJMAN AND CA-OPU2 (MR SCOFIELD)

1. Safety of blood

Medical advice on HCV lookback and litigation.

Provision of medical advice on all aspects of prevention of infection of blood recipients, including advice on deferral of donors, screening blood tests, etc. Contribution and comment on PO jackets, PQs, as appropriate.

Medical Secretary of Committee on Microbiological Safety of Blood and Tissues for Transplantation, covering safety of blood as well as tissues and organs.

This SLA should transfer to HP on the basis of recommendations of the Banks Report.

### Supply of blood

Medical Departmental input into supply of blood and NBA reorganisation.

Attendance at NBA meetings as an observer.

### 3. Haemophilia

Professional advice on all aspects of haemophilia treatment.

Contributions to POs, PQs etc on this subject.

Attendance at meetings of the Regional Haemophilia Directors Organisation, the Haemophilia Centre Directors Organisation and other haemophilia meetings, ensuring that departmental views are made known to the members.

### Safety and efficacy of fractionated blood products

Medical advice on these matters liaising with MCA as appropriate.

Attendance at EU meetings of CPMP Biotechnology/Pharmacy Working Party where appropriate.

This SLA should transfer to HP on the basis of recommendations of the Banks Report.

### HIV blood transfusion payment scheme

To investigate applications for payment under this scheme.

To present a case for payment or non payment to Mrs A James of SOLB prior to decision by Mr Scofield on behalf of Secretary of State.

#### DRAFT SLA BETWEEN DR A REJMAN AND SCS-B3

#### Haemoglobinopathies

To give medical advice on provision of services for patients suffering with haemoglobinopathies.

To act as Chairman of the Haemoglobinopathy Card Working Party, and following consultation to contribute to a submission to PS(L) on the revised card.

# DRAFT SLA BETWEEN DR A REJMAN AND HCD-SCS-A

To provide medical advice on all aspects of leukaemia and bone marrow transplantation.

To provide contributions to POs and PQs on these topics.

To provide advice in preparing a departmental line on the use of children as sibling bone marrow donors.

#### DRAFT SLA BETWEEN DR A REJMAN AND MDA

# 1. IVD Directive

To be a member of the Risk Assessment Working Party highlighting the importance of HIV, HBsAg and HCV testing together with ABO and rhesus D typing in Annex 2 of the Directive.

# 2. Equipment evaluation

To act as advisor to MDA or medical project officer on evaluation of haematology and blood transfusion equipment, as well as attending BCSH who now have the overall responsibility for nominating evaluation centres.

### 3. Testing Kits

To advise MDA about the VRL evaluation of HIV and HCV testing kits for blood donation, together with advice on proposals on harmonisation of testing kit requirements across EU, Council of Europe and WHO.

# Storage of bone marrow

To complete work as Chairman of the Working Party on Collection, Storage and perfusion of bone marrow, by advising on consultation and issue as guidance to the NHS.

### DRAFT SLA BETWEEN DR A REJMAN AND IRUI

Council of Europe aspects of blood safety and provision.

To give advice and briefing to Ministers and administrators in respect of Council of Europe interests in these matters.

Attendance as member of Committee of Experts in Blood Transfusion and Immunohaematology (SP-HM) and its Bureau.

### DRAFT SLA BETWEEN DR A REJMAN AND IRU2

# EU aspects of blood safety and provision.

To provide advice and briefing for Ministers and officials in respect of EU interests in these topics.

To attend meetings as a member of the Committee on Blood Self-Sufficiency in the European Community and to collate information for questionnaires on these topics.

#### DRAFT SLA BETWEEN DR A REJMAN AND HEF

# Anticoagulant Card.

Providing medical input on this topic, and attendance at the BCSH Task Force on Thrombsis and Haemostatis to ensure appropriate updating by the profession.

# NIBSC

To act as "intelligent customer" for the work of NIBSC in the blood field, where that work is of a policy nature outside the sphere of the NBA. This topic is the subject of an SLA between DH and NIBSC.

# DRAFT SLA BETWEEN DR A REJMAN AND CA-OPU3

# PCR Licensing Agreement.

To provide medical input into the discussions on the proposed model license being negotiated with Roche.

### NUMBER OF HOURS FOR SLAS

# **Hours**

# CA-OPU2 (\* with HP in future)

*	Safety of Blood and MSBT		14.5
	NBA		2.0
	Haemophilia		2.5
	Safety of Fractionated blood products		2.5
	HIV payment scheme	1.0	
IRU1	• •		1.8
IRU2			1.8
MDA		1.0	
HEF			0.2
CA-OPU3			0.5
SCS-A		3.1	
SCS-B	3		1.3